Polyunsaturated Fatty Acid-derived lipid mediators and T cell function.
Nicolaou, A; Mauro, C; Urquhart, P; Marelli-Berg, F

For additional information about this publication click this link.
http://qmro.qmul.ac.uk/jspui/handle/123456789/6582

Information about this research object was correct at the time of download; we occasionally make corrections to records, please therefore check the published record when citing. For more information contact scholarlycommunications@qmul.ac.uk
Polyunsaturated fatty acid-derived lipid mediators and T cell function

Anna Nicolau1*, Claudio Mauro2, Paula Urquhart1 and Federica Marelli-Berg2

1 Manchester Pharmacy School, Faculty of Medical and Human Sciences, The University of Manchester, Manchester, UK
2 Centre for Biochemical Pharmacology, William Harvey Research Institute, Queen Mary University of London, London, UK

INTRODUCTION
The regulation of energy metabolism is crucial to T cell-mediated immunity including activation, proliferation, and differentiation (1). Following recognition of antigen in the lymph nodes, naïve T lymphocytes undergo massive clonal expansion and differentiation, followed by a contraction or death phase, and the establishment and maintenance of immunological memory (2, 3). Before undergoing division, T cells activate biosynthetic pathways for the production of proteins, nucleic acids, lipids, carbohydrates, and other “building blocks” necessary for the generation of new cells. Following this stage, the metabolic machinery of T cells is reprogrammed, switching from the β-oxidation of fatty acids in naïve T cells to the glycolytic pathways in activated T cells (4–6).

Downstream of T cell receptor (TCR) signaling, phosphatidylinositol 3’-kinase (PI3K) leads to the activation of the serine–threonine kinase AKT, which promotes glucose metabolism by stimulating the localization of the glucose transporter Glut1 to the plasma membrane, and the activity of hexokinase and phosphofructokinase, two rate-limiting enzymes of the glycolytic pathway. Increased glycolytic flux enables activated T cells to generate ATP and, at the same time, efficiently utilize carbon sources in the form of amino acids and lipids for the biosynthesis of proteins and membranes necessary for the expansion phase that characterizes the immune response (7–11). AKT also controls the activation state of mammalian target of rapamycin (mTOR), a sensor of nutritional and energetic status in cells that promotes protein synthesis.

Fatty acids are involved in T cell biology both as nutrients important for energy production as well as signaling molecules. In particular, polyunsaturated fatty acids are known to exhibit a range of immunomodulatory properties that progress through T cell mediated events, although the molecular mechanisms of these actions have not yet been fully elucidated. Some of these immune activities are linked to polyunsaturated fatty acid-induced alteration of the composition of cellular membranes and the consequent changes in signaling pathways linked to membrane raft-associated proteins. However, significant aspects of the polyunsaturated fatty acid bioactivities are mediated through their transformation to specific lipid mediators, products of cyclooxygenase, lipoxygenase, or cytochrome P450 enzymatic reactions. Resulting bioactive metabolites including prostaglandins, leukotrienes, and endocannabinoids are produced by and/or act upon T leukocytes through cell surface receptors and have been shown to alter T cell activation and differentiation, proliferation, cytokine production, motility, and homing events. Detailed appreciation of the mode of action of these lipids presents opportunities for the design and development of therapeutic strategies aimed at regulating T cell function.

Keywords: T cells, polyunsaturated fatty acids, eicosanoids, prostaglandins, leukotrienes, cyclooxygenase, lipoxygenase, endocannabinoids
omega-3 polyunsaturated fatty acids (n-3 PUFA) are recognized as modulators of inflammation and immunity mediating their pleiotropic activity through regulation of gene expression, influencing signaling cascades, and altering the composition of the cellular membranes (20, 21). The latter has implications for the structure and function of the membrane, as well as a direct impact on the production of n-6 and n-3 PUFA-derived bioactive lipids including PG, leukotrienes (LT), resolvins (Rv), protectins (PD), endocannabinoids, and related congeners.

Although the immunomodulatory properties of PUFA have been known for many years, the molecular mechanisms underlying these properties are not fully understood. It has been shown that n-3 PUFA suppress antigen presentation, T cell activation and proliferation, and lower the expression of signature cytokines (21–27). Disappointingly, early studies using daily supplementation with foods rich in n-3 PUFA failed to show significant improvement in organ transplantation rejection (28, 29). However, recent reports indicate that administration of purified eicosapentaenoic acid (EPA; 20:5n-3) induces the differentiation of regulatory T cells through upregulation of peroxisome proliferator-activated receptor γ (PPARγ), a ligand-activated nuclear receptor that regulates lipid and glucose metabolism, leading to increased allograft survival (30, 31).

Following this direction, studies have explored the effect of cellular incorporation of the main n-3 PUFA, EPA, and docosahexaenoic acid (DHA; 22:6n-3). These fatty acids can alter the composition and molecular organization of membrane rafts with a consequent impact on the activity of raft-associated signaling proteins and related events. Examples include recruitment and activation of PLCγ and F-actin, impairing mitochondrial translocation necessary to maintain Ca2+ signaling for NFkB and AP-1 activation and IL-2 secretion, and suppression of phosphatidylinositol- dependent actin remodeling, all linked to reduced CT4+ T cell activation [recently reviewed in Ref. (20)]. Importantly, many of the PUFA mediated activities are conveyed through their metabolites that tend to be produced and metabolized upon request, can act near the site of their synthesis or transported via circulation and in this way mediate systemic effects (autacoids). These families of potent mediators are intimately involved in inflammation and immunity, with pro- and/or anti-inflammatory, proliferative, and chemotactic/active activities (21).

Overall, these new findings suggest that a better understanding of the molecular mechanism of action of PUFA may lead to the development of effective therapeutics. In this article, we will overview the current knowledge of the function and impact of eicosanoids and related metabolites, as well as that of endocannabinoids and their congeners on T cell function, and examine potential applications in biomedical research.

**PUFA-DERIVED LIPID MEDIATORS: BIOSYNTHESIS AND METABOLISM**

The cellular membrane serves as a pool of PUFA available for further metabolism to various bioactive lipids. These potent autacoids act as local hormones and are produced upon request following the activation of signaling pathways or effect of environmental and other stimuli. The arachidonic acid (AA; 20:4n-3)-derived eicosanoids are some of the best known and studied bioactive lipids. The term “eicosanoids” is used to describe the bioactive derivatives of three fatty acids with 20-carbon acyl chains, namely: AA, EPA, and dihomo-gamma linolenic (DGLA; 20:3n-6). These metabolites, although mostly linked to inflammation, are also involved in cell migration, proliferation, chemotaxis, and immune reactions (32–34). Eicosanoids and related mediators derive from the activities of cyclooxygenases (COX), lipoxigenases (LOX), and cytochrome P450 (CYP) epoxygenases and mono-oxygenases (Figures 1 and 2) [reviewed in Ref. (35)]. The term “endocannabinoids” refers to endogenous lipids ligands of the cannabinoid receptors CB1 and CB2. These are also derivatives of AA, while other PUFA ethanolamides are now recognized as members of this family (36). Although endocannabinoids can be metabolized by COX and LOX, their precursor phospholipids and metabolism are different to eicosanoids (Figure 3).

**CYCLOOXYGENASE-MEDIATED FORMATION OF PROSTANOIDS**

The eicosanoid cascade starts with the activation of phospholipases (PL), predominantly PLA2 but also PLD and diacylglycerol (DAG) lipase that release AA and other PUFA from the cellular membrane (35). The family of PLA2 comprises a large number of enzymes with distinct characteristics in terms of their activation, cellular localization, and substrate specificity (37). There is evidence for the presence of various PLA2 isoforms in primary T cells and the Jurkat T cell line, including cPLA2, sPLA2, and iPLA2 (38–42). Inducible isoforms of PLC and DAG lipase have also been identified in tumor and peripheral T lymphocytes (42, 43).

Free AA is then metabolized via the constitutive and inducible COX isoforms (COX-1 and -2, respectively) to the unstable endoperoxide PGH2 that is then transformed to PG, thromboxanes (TX), and prostacyclin (PGL2) via tissue specific terminal prostaglandin synthases (Figure 1); these COX-derived mediators belong to the family of eicosanoids and are collectively known as prostanooids. Apart from AA, prostanooids are formed from the other two 20-carbon containing PUFA, DGLA, and EPA, with the resulting metabolites having different activities and being considered less-inflammatory than the AA-derived ones (35, 44).

The exact profile of prostanooids is determined by the prevalence of specific synthases in the cell type or tissue of interest. PGE2 is produced by prostaglandin E synthase (PGES) that is found as membrane bound (mPGES-1 and -2) or cytosolic (cPGES). mPGES-1 is an inducible isoform and is frequently found co-expressed with COX-2 (45, 46). PGD2 is produced by the hematopoietic-type (H-PGDS) or the lipocalin-type (L-PGDS) synthases (47), while further non-enzymatic hydrolysis of PGD2 gives rise to the anti-inflammatory cyclopentaneone PGs PGJ2 and 15d-PGJ2 (48, 49). PGF2α is produced either directly from PGH2 via the prostaglandin F synthase (PGFS) or through further metabolism of PGE2 and PGD2 by PGE 9-ketoreductase and PGD 11-ketoreductase, respectively (50). Prostacyclin (PGI2) is produced via the prostacyclin synthase (PGIS) and is usually detected as its stable but inactive metabolite 6-keto-PGF1α (51). Finally, thromboxane synthase (TXS) converts PGL2 to TXA2, an unstable prostanooid that is quickly hydrolyzed to the stable but inert metabolite TXB2 (51). The bioactivity of prostanooids is mediated through G protein-coupled receptors for PGE2, PGD2, PGF2α, PGI2, and TXA2, designated EP, DP, FP, IP, and TP,
FIGURE 1 | Schematic representation of the main biochemical pathways that mediate the production of prostanoids. COX, cyclooxygenase; PGES, prostaglandin E synthase; PGDS, prostaglandin D synthase; PGFS, prostaglandin F synthase; PGIS, prostacyclin synthase; TXS, thromboxane synthase.

FIGURE 2 | Schematic representation of the main biochemical pathways that mediate the production of mono-hydroxy fatty acids and leukotrienes (A), and the poly-hydroxy fatty acids lipoxins, resolvins, and protectins (B), products of transcellular metabolism.

respectively. Pharmacological studies into their ligand-binding profiles and signal transduction pathways, and genetic analysis led to their classification into eight groups (EP1, EP2, EP3, EP4, DP1, FP, IP, and TP) although new developments have revealed the presence of a second PGD receptor, DP2, and the presence of heterodimers (52, 53). Overall, prostanoids are potent autacoids and their levels are controlled through enzymatic catabolism via dehydrogenations and reductions resulting in the formation of
metabolites with significantly reduced bioactivities (e.g., 15-keto- and 13,14-dihydro-15-keto PGs) (54).

**LIPOXYGENASE-MEDIATED PRODUCTION OF LEUKOTRIENES AND OTHER HYDROXY FATTY ACIDS**

Lipoxygenases mediate the oxygenation of free fatty acids including AA and other PUFA. Their activities are commonly defined by their positional selectivity when they oxygenate AA and, following this system, the main mammalian LOX enzymes are defined as 5-, 12-, and 15-LOX. They catalyze the stereoselective insertion of OH in the S configuration, with the exception of a mammalian skin-specific enzyme 12R-LOX. The products of LOX reactions are unstable hydroperoxides that are then reduced to hydroxy acids (55–57) (Figure 2). 5-LOX acts in concert with 5-lipoxygenase activating protein (FLAP) to metabolize AA to 55-hydroperoxyeicosatetraenoic acid (HPETE) that is further reduced to 55-HETE or dehydrated to LTA4, an unstable epoxide containing a conjugated triene system characteristic of all LT. LTA4 can be metabolized to LTE4 or form the cysteinyl LT, LTC4, LTD4, LTE4 following conjugation with reduced glutathione (58). 55-HETE can be also enzymatically reduced to the 5-oxo-eicosatetraenoic acid (5-oxo-ETE), a chemoattractant mediator (59). Mammalian 12- and 15-LOX isozymes oxygenate a range of PUFA, both free and esterified in membrane phospholipids and lipoproteins (57), forming a multitude of mono- and poly-hydroxy fatty acids: e.g., AA produces hydroxyeicosatetraenoic acids (HETE), EPA generates hydroxyeicosapentaenoic acids (HEPE), DHA produces docosanoids including hydroxydocosahexaenoic acids (HDHA), linoleic acid (LA; 18:2n-6) forms octadecanoids such as hydroxy octadecadienoic acids (HODE), DGLA forms hydroxyeicosatrienoic acids (HETE), etc.

**CYTOCHROME P450 MEDIATED FATTY ACID EPOXIDES AND THEIR DERIVATIVES**

Cytochrome P450 mono-oxygenases relevant to PUFA metabolism catalyze epoxigenations and mid-chain and omega-hydroxylations producing a range of LOX-like mono-hydroxy fatty acids (e.g., HETE, HEPE, HODE) although not necessarily of the S configuration [reviewed in Ref. (35)]. Interestingly, partially inhibited COX-2 (e.g., acetylated COX-2 following treatment with aspirin) can also generate LOX-like products with the OH group at R configuration, e.g., 15R-HETE from AA and 18R-HEPE from EPA (60). These metabolites are important in aspects of transcellular metabolism where sequential LOX/LOX or acetylated COX-2/LOX or CYP/LOX reactions involving more than one cell types are involved in the formation of multi-hydroxy fatty acid species. These include the lipoxins (LX) that are tri-hydroxytetraene-products of AA, and the di- and tri-hydroxy-PUFA termed Rv, PD, and maresins (MaR) that are derivatives of EPA and DHA. All these mediators are involved in inflammation and immunity exhibiting a range of protective roles (61–63).

**THE ENDOCANNABINOIDS**

The endocannabinoids anandamide (arachidonoyl ethanolamide, AEA) and 2-arachidonoyl glycerol (2AG) are derivatives of AA and act as endogenous ligands to the cannabinoid receptors CB1 and CB2 [reviewed in Ref. (36)]. This family of bioactive lipids has been extended to include other fatty acid ethanolamides and glycerols, while recent findings regarding their metabolism suggest a wider involvement in inflammation and immunity. The biochemical precursors of AEA and its congeners are various N-acylated ethanolamine phospholipids (NAPE) that found in very low concentrations in the biological membranes and are hydrolyzed by NAPE-specific PLD or PLC-type lipases. 2AG production is mediated by PLC-diaclyglycerol lipase. AEA and 2-AG can be deactivated via hydrolysis mediated by fatty acid amide hydrolases (FAAH) or can be metabolized by COX-2 to generated prostaglandin ethanolamides known as prostamides (e.g., PGE2-EA) and prostaglandin glyceryl esters (e.g. PGE2-GE) (Figure 3) (52). LOX isozymes can also metabolize these lipids although the
prevalence and bioactivities of the resulting mediators remain to
be explored.

**EICOSANOIDS AND RELATED MEDIATORS IN T CELL
FUNCTION/BIOLOGY**

**PROSTANOIDS**

It is now recognized that resting and activated T cells express the
COX-1/-2 system (64–68). Although the constitutive COX-1 is not
affected during T cell activation, the inducible COX-2 is upregu-
lated as has been shown in studies with CD4+ cells, Jurkat T
cells and adaptive Tregs (66–69). To date, very little is known
about the exact profile of prostanoids produced by T cells with
only a few studies reporting the production of PGE2, PGD2 and
its dehydration product 15d-PGJ2, as well as low levels of TXA2
(67, 68, 70). There is also very little information on the type of
prostanoid synthases expressed in T cells, including evidence for
H-PGDS and PGES in Tregs (67, 68). However, a number of stud-
ies have explored the role of PGE2, PGD2, PGJ2, PGF2α, and TXA2
on various aspects of T cell function, showing that prostanoid-
mediated effects process through receptors and related signaling
pathways expressed in most T cell populations and subtypes.
Interestingly, it has been shown that treatment with AA upregulates
the CXCNR3/1 inducible chemokine receptors expressed in CD4+ T
cells and increases their chemotactic responses through a COX-
related pathway (71), suggesting a potential role for this pathway
in the regulation of T cell migration.

**PGE2**

Although considered to be a, primarily, pro-inflammatory
eicosanoid, PGE2 can also mediate anti-inflammatory signals, and
is a potent immunosuppressor (72). PGE2 is one of the best-
studied bioactive lipids in T cell biology, exhibiting a multitude
of effects. It is involved in the early stages of T cell development in
the thymus, where it stimulates the differentiation of CD4+CD8+ thymocytes (73), while in later stages it regulates the develop-
ment and balance of Th1, Th2, and Th17 subsets (74–76) and,
overall, influences proliferation, differentiation, cytokine produc-
tion, and apoptosis of mature T cells (14, 77–80). Interestingly,
the activity of PGE2 on T cells appears to be concentration-
dependent: while at low concentrations, it is involved in home-
ostatic events and inhibits the activation and differentiation of T
lymphocytes, at high concentrations, PGE2 has the opposite effect,
increasing T cell proliferation, and suppressing immune functions
[recently reviewed in Ref. (81)]. For example, in ultraviolet radia-
tion (UVR)-induced immunosuppression, impaired development
of peripheral memory T cells can be attributed to UVR-induced
PGE2 production (82).

Antigen presenting dendritic cells (DC) and macrophages
secrete PGE2 and in this way can influence proliferation and dif-
ferentiation of CD4+ and CD8+ cells, and direct the balance of
Th1, Th2, and Th17 cell subtypes (14). PGE2 can also affect the
maturation of DC and alter DC-produced cytokines, thus influ-
encing the differentiation of T cell subtypes: for example, DC cells
matured in the presence of PGE2 in vitro promote Th17 and inhibit
Th1/Th2 polarization (78). PGE2 can also enhance the prolifera-
tion of T cells through the induction of costimulatory molecules
OX40L, CD70, and 4-1BBL on DC (83), while other studies have
reported that PGE2 inhibits the ability of DC to produce CCL19
and attract naive T cells (84). Interestingly, the ratio DC:T cells
appears to be crucial in determining the overall immunogenic
effect of PGE2: it has been reported that at high DC:T cell ratios,
PGE2-matured DC cells inhibit the proliferation of T cells, while,
when this cell ratio is low, an enhanced T cell stimulation is
observed (85). A dose-dependent effect has also been observed in
the way PGE2 mediates the balance Th1 to Th2 subtypes: high
levels of PGE2 suppress Th1 cell differentiation and polarization,
shifting the immune response toward a Th2 phenotype (79).
These observations have been confirmed in vivo using COX-2 inhibitors
(e.g., celecoxib) and COX-2 knockout models demonstrating that
when PGE2 production is reduced, an increase in Th1 responses is
observed [reviewed in Ref. (81)]. The regulation of Th2 cells by
PGE2 is likely to impact in Th2-mediated immune disorders
such as atopic dermatitis and asthma (86, 87). Finally, when PGE2
is produced by activated macrophages it reduces T cell activation
and proliferation; this in turn leads to a reduction in cytokine pro-
duction and consequent reduced stimulation of macrophages in a
negative feed-back loop (72).

In vivo work has elucidated the role of EP receptors in mediating
PGE2 effects. PGE2 produced by DC in the lymph node acts
through the EP1 receptor to promote the differentiation of naive T
cells to Th1 cells (88). Studies on the BALB/c mice, a strain show-
ing propensity to generate Th2 responses, have shown that Th2
cells express high levels of EP2 and that PGE2 signaling through
this receptor protects Th2 cells against activation induced cell
death (77). Furthermore, in a model of experimental autoimmune
encephalomyelitis (EAE), PGE2 signaling through EP4 was shown
to exert a dual role: promoting immune inflammation through
Th1 cell differentiation and Th17 cell expansion during the induc-
tion phase. In contrast, during the effector phase of the disease, it
attenuated the access of these pathogenic T cells to the brain by
protecting the blood brain barrier (89, 90).

PGE2-induced effects mediated via the EP2/EP4 receptors are
linked to cAMP concentration and related signaling (53). In cyto-
toxic T cells, PGE2 and other CAMP activators trigger increased
concentration of cAMP and this interferes with the cytoskeleton
function and terminates cytotoxic T cell secretion and adhe-
sion (91). Dietary interventions with n-3 and n-6 PUFA can
alter the cell membrane composition with consequent changes
in the concentration of PGE2 produced, as well as the preva-
ence of the less-inflammatory PGE species, PGE1 and PGE3 (44).
Although frequently cited as anti-inflammatory, these species do
not always appear to be different in their immunomodulatory
properties: for example, studies have shown that both PGE2 and
PGE1 suppress mitogen-induced blastogenesis in T cells, an effect
confirmed with experiments using indomethacin, a non-specific
COX inhibitor (92).

PGE2 ethanolamide appears to be also involved in the motility
of T cells (93, 94) and recent work using imaging has identified
PGE2 as an antagonist of the T cell migration stop signal (95).
This activity was shown to be subset specific, with Th migration in
response to IL-2 inhibited at 10–100 ng/ml PGE2 in vitro, although,
in the same experimental conditions, the migration of cytotoxic
T cells was not affected (96, 97). PGE2 has also been suggested to
inhibit the transendothelial migration of T cells through increased
calcium and cAMP concentrations (98, 99). In rats, PGE2 was found to inhibit the migration of T cells across the microvascular retinal endothelial cells although it did not affect the expression of adhesion molecules on either endothelial or T cells (100). However, PGE2 at nanomolar to micromolar concentrations elicited migration of T cells in vitro and increased secretion matrix metalloproteinas (MMP); although MMP inhibitors suppressed the transmigration, the inhibition did not affect the PGE2-initiated T cell motility (101). Finally, overexpression of COX-2 in a mouse breast cancer model increased the recruitment of Tregs in the tumor, an effect mediated via EP2 and EP4 receptors (102).

PGD2 and 15d-PGJ2

PGD2 is considered an immunomodulatory prostaglandin and some of its cyclopentanone PG metabolites, such as 15-deoxy-Delta12,14-PGJ2 (15d-PGJ2), are endowed with anti-inflammatory activities (49, 103). Production of PGD2 has been detected in Th2 cells and this was linked to expression of H-PGDS, while L-PGDS has not been identified in any T cell subtype (67, 104, 105). The downstream product of PGD2 dehydration, 15d-PGJ2, has also been detected in human T cell cultures (67).

PGD2 mediates its effects through two receptors DP1 and DP2, the latter better known as chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2). DP1 belongs to the prostanooid family of receptors, signals through cAMP and has been detected in Th1, Th2, and CD8+ cells (106). DP2/CRTH2 has little similarity to prostanooid receptors and belongs to the cytokine receptor family; it signals through increased calcium and inhibition of cAMP and has been found to be preferentially expressed by activated Th2 cells mediating their recruitment and motility (106, 107). While PGD2 can signal through either receptor, findings to date indicate that 15d-PGJ2 activates only DP2 (103). It has been suggested that PGH2 may also be an agonist of DP2 (108). PGD2 and 15d-PGJ2 are also agonists of PPARγ and can induce differentiation of fibroblasts to adipocytes; this has been shown in the case of Grave’s disease where it was reported that activated T cells drive fibroblast differentiation in ocular tissue through production of PGD2 and 15d-PGJ2, implying that T cell infiltrates can influence fat deposition in other tissues (67).

PGD2 can mediate different effects depending on the target receptor and related signaling events (109). DP1 can induce differentiation of Th2, whilst DP2/CRTH2 is mostly involved in their recruitment, although the two receptors may exert opposing effects, as examined in an animal model of contact hypersensitivity where DP2/CRTH2 appeared to mediate inflammatory events while DP1 was inhibitory (110). Furthermore, both receptors have been reported involved in T cell proliferation, and DP1 has been suggested to promote T cell apoptosis and downregulate immune responses, while DP2 has been reported to delay Th2 apoptosis (111). A potentially anti-inflammatory protective effect of 15d-PGJ2 in pregnancy has been attributed to its suppression of Th1 response and promotion of Th2 immunity through DP2 (112).

Activation of Th2 cells by PGD2 is thought to occur predominantly through DP2/CRTH2 with concomitant increase in the production of cytokines and pro-inflammatory proteins (106, 113–115). PGD2 binding to this receptor is also very important for CD4+ T cell trafficking and motility (116, 117). When produced at high concentrations by mast cells, as seen in allergic inflammation, there is a consequent activation and recruitment of Th2 cells toward the PGD2 producing sites (118, 119). Activated T cells can also produce PGD2 and this may promote further accumulation of Th2 in the inflamed tissue (107, 116).

Finally, PGD2 has been shown to affect the maturation of monocyte derived DC impacting on their ability to stimulate naive T cells and favoring their differentiation toward Th2 cells (120, 121). Interestingly, age related increase in PGD2 levels have been associated with decreased DC migration and reduced T cell responses in a mouse model of respiratory infections, suggesting that inhibition of PGD2 functions may be an effective therapeutic approach (122).

PGF2α

To date, there is very limited information on the contribution of this vasoactive prostaglandin on T cell function. There are no reports on the production of PGF2α or expression of the relevant synthases on T lymphocytes. Early work exploring the involvement on PG on T cell locomotion considered the involvement of PGF2α but this was not supported by the resulting data (93). However, a recent report on allergic lung inflammation presents evidence for the contribution of PGF2α in Th17 cell differentiation, an autocrine effect mediated through cell surface FP receptors (123).

PGL2

PGL2 is best known as an inhibitor of platelet aggregation and potent vasodilator, while recent finding has shown its involvement in immune regulation with particular importance in airway inflammation. The IP receptor is expressed in a number of immune cells in the lung, including T lymphocytes of the Th1 and Th2 lineage (124, 125). However, there is very little information on the actual production of PGL2 by T cells with only some indirect evidence for possible transcellular biosynthesis operating between platelets and lymphocytes, and some recent work showing PGL2 mRNA in an animal model of contact hypersensitivity (125, 126).

Studies in various models suggest that PGL2 is involved in regulating the balance of Th1 and Th2 responses, as well as promoting Th17 cell differentiation (13, 127). Work in a mouse model of asthma has shown that PGL2 produced by endothelial cells and signaling through the IP receptor prevents the recruitment of Th2 in the airways (128). However, a mouse model of contact hypersensitivity shows that in cutaneous disease PGL2–IP signaling raises intracellular cAMP concentration and promotes Th1 differentiation (125). Furthermore, PGL2 increased the ratio of IL-23/IL-12 leading to differentiation of Th17 cells and exacerbation of EAE in mice (129). Finally, the anti-inflammatory effect of PGL2 has been explored through analogs that reduced the production of pro-inflammatory cytokines and chemokines by DC, increased the production of anti-inflammatory IL-10, and inhibited their ability to stimulate CD4+ T cell proliferation (124).

TXA2

Although production of TXA2 by T cells has been reported, albeit at very low levels, the expression of the relevant synthase has not yet been shown (70, 130). However, the TP receptor has been
found in a range of T cell populations and a polymorphism identified in Th2 cells has been linked to aspirin-exacerbated respiratory disease (130–133). Work with human lymphocytes suggested that TXA₂ is involved in the inhibition of T cell proliferation and related cytokine production (134). Following production of TXA₂ by DC, stimulation in TP expression was observed and this appeared to be involved in the random movement of naive but not memory T cells, suggesting that TXA₂ can mediate DC–T cell interactions (130).

**LEUKOTRIENES, HYDROXY FATTY ACIDS, LIPOXINS, RESOLVINS, AND PROTECTINS**

Lipooxygenase isoforms identified in various T cell populations include 5-, 12-, and 15-LOX (135–138). Although some early studies suggested that externally provided AA could inhibit 5-LOX, recent reports have indicated that provision of substrate may be necessary for the synthesis of LTs (135, 139). There is evidence that 5-HETE, LTA₄ and LTB₄, and the cysteinyl LT LTC₄, LTD₄, and LTE₄ are produced by human and animal primary T cells and cell lines (43, 135, 138, 139). Furthermore, the presence of 5-LOX and 12/15-LOX would suggest the production of hydroperoxy- and hydroxy-PUFA by T cells. Nevertheless, there are not many studies examining the formation of such mediators and the majority of relevant reports focus on the effect of 12- and 15-HETE, LX, resolvins, and PD on T cell function.

**LTC₄, LTD₄, LTE₄**

The main activity attributed to LTB₄ is chemotaxis, a property mediated through the high affinity receptor BLT1 that is expressed in many CD4⁺ and CD8⁺ T cell subtypes (140–143). BLT1 is also important for homing events, as it enables the adhesion of T cells to epithelial cells, and appears of particular importance for the recruitment and direction of T cells to the airways in asthma (141, 144). Blockade of LTB₄/BLT1 pathway has also been shown to improve CD8⁺ T cell mediated colitis (145). Finally, LTB₄ appears involved in Th17 cell differentiation, Th1 and Th2 proliferation, and cytokine production (146–149).

**5-HETE and 5-oxo-ETE**

Oxidative stress appears to stimulate the metabolism of 5-HETE to 5-oxo-ETE in peripheral blood lymphocytes, although the role of this lipid mediator in T cell function is not clear (156, 157).

**12-, 15-HETE**

12-HETE has been involved in T cell function, with particular relevance to allergic disease. Although 12(S)-HETE is a neutrophil chemoattractant it does not appear to have a similar effect on T cells. Work on skin-derived lymphocytes involved in psoriasis has shown that 12(R)-HETE, a 12R-LOX product found in psoriatic skin, has modest chemotactic properties for T cells but is less potent than LTB₄ (158, 159). Furthermore, it has been shown that inhibition of 12/15-LOX enhanced the production of Th2 cytokines and attenuated the development of allergic inflammation in a mouse model of allergic lung disease, whilst delivery of 12(S)-HETE had the opposite effect (136). Increased levels of 12-HETE were also associated with metabolic changes in T cells leading to development of autoimmune disease (137).

It has been reported that 15-HETE regulates T cell division and displays anti-proliferative effects on a leukemia T cell line (160–162). Metabolism of 15-HETE through β-oxidation has been observed in blood T cells leading to the hypothesis that the resulting β-hydroxy acids and their oxidized and decarboxylated products may play a role in T cell biology (163). 15-LOX metabolites have also been involved in Th1 responses in a mouse model of Th1 allergic inflammation induced by double-stranded RNA (164).

**Lipoxins**

Although not directly produced by T cells, LXA₄ has been shown to interact with the LTB₄ receptor expressed in T cells (165, 166). Aspirin-triggered LXA₄ and LXB₄, and stable analogs, inhibited TNFα production by human peripheral blood T cells suggesting the involvement of these metabolites in T cell mediated inflammation (167). Finally, LXA₄ appears to be involved in Treg-mediated tumor protection through the induction of myeloid suppressor cells, as shown in a murine liver cancer model (168).

**Resolvins and protectins**

These products of EPA and DHA are formed through transcellular metabolism and some of their anti-inflammatory and pro-resolution effects are mediated through their effects on T cells. It has been reported that PD1 is formed by Th2-skewed peripheral blood mononuclear cells and appeared to block T cell migration, inhibit TNFx and IFγ secretion, and promote apoptosis in vivo (169). Reduction of CD4⁺ and CD8⁺ T cell infiltrates and CD4⁺ T cell-produced cytokines was also observed in a mouse model of DNFβ-induced atopic dermatitis treated with RvE1 (170). Furthermore, RvE1-treated bone marrow-derived DC appear to induce apoptosis of T cells, and it has been suggested that instead of migrating to the lymph nodes they remain on the inflammatory sites targeting the infiltrating effector T cells (171). RvE1 has also been shown to reduce the influx of Th1 and Th17 cells in the cornea of a mouse model of stromal keratitis, a virally induced immunopathological disease; it has been suggested that this may have contributed to a significant reduction in lesions observed (172).

**ENDOCANNABINOIDS AND CONGENERS**

The endocannabinoid system is considered an important regulator of the immune response with AEA, 2AG, and related enzymes and receptors being involved in T cell function (173–176). Production of AEA and 2AG have been shown in human T lymphocytes.
Work with activated primary human T lymphocytes has shown that AEA and its congeners, palmitoyl- and oleoyl-ethanolamide, were important mediators of T cell subsets including splenic memory CD4+ cells and natural killer T cells (182). Interestingly, a common CB2 gene polymorphism has been linked to reduced immune modulation by endocannabinoids and may be a risk factor for autoimmune disorders (183). Finally, FAAH and monoacylglycerol lipase (MAGL) are also present in human T lymphocytes (179). FAAH appears to play a protective role controlling the levels of AEA in pregnancy as well as immune-mediated liver inflammation (178, 184).

**AEA and congeners**

Work with activated primary human T lymphocytes has shown that AEA can suppress T cell proliferation and cytokine release in a CB2-dependent manner, without exerting cytotoxic effects (185, 186). However, other studies suggested that AEA inhibits T cell proliferation and induces apoptosis through a mechanism that may not be receptor mediated but most probably related to lipid rafts (187, 188).

The immunosuppressive effect of AEA extends to Th17 cells and this is of particular interest for the development of immunotherapeutic approaches (186). Endogenous AEA or inhibition of FAAH leading to increased AEA levels, were effective in reducing cytokine levels, decreased liver injury, and increased numbers of Treg cells in a murine model of immune-mediated liver inflammation (184). AEA inhibited the migration of CD8+ T cells in a collagen-based migration assay, again through the CB2 receptor (189). However, a study evaluating the direct anti-cancer potential of AEA, reported no effect on lymphocyte proliferation or Treg generation or cytokine production (190). In contrast, other studies have reported proinflammatory effects by AEA. In a mouse model of atherosclerosis, reduced levels of FAAH that resulted in increased AEA and its congeners, palmitoyl- and oleoyl-ethanolamide, were accompanied by reduced CD4+FoxP3+ regulatory T cells, suggesting a pro-inflammatory effect on the overall immune response (191). In addition, AEA appears to promote Th1 immunity as shown in a model of sensitization where it was reported to induce DC activation and IFNγ production (192). Finally, a recent study with bimatoprost suggested that this prostamide can induce calcium signaling in human T cells (193).

**2AG**

The chemotactic properties of 2AG are also mediated through the CB2 receptor and this has been shown in various immune cells including migration of splenocytes (194), homing of B cells (195), and motility of human natural killer cells (196). When this potential was assessed in activated T lymphocytes, it was reported that although 2AG did not induce T cell migration, it inhibited migratory responses toward the chemokine CXCL12, suggesting a possible regulatory role in T cell migration (179). Furthermore, 2AG can act as DC chemoattractant and indirectly shift the memory response toward a Th1 phenotype in a CB2-mediated fashion (197). 2AG can also suppress IL-2 production in Jurkat cells through PPAR-γ activation and independently of CB1 and CB2-mediated signaling (198). The contribution of a COX-2 metabolite of 2AG has also been considered by recent reports confirming that the 15-deoxy-delta(1)(2)(1)(4)-PGJ2-glycerol ester (15d-PGJ2-GE) is a PPAR-γ ligand that suppresses IL-2 production in activated Jurkat cells (111, 199).

**CONCLUDING REMARKS**

While current evidence support a key role for PUFA-derived bioactive lipids in the regulation of T cell immunity (Table 1), the complexity of their biological properties and the lack of a comprehensive understanding of their exact contribution to different stages of the immune response hinders the identification of mediators of interest either as markers or as target compounds for drug development. In general, it appears that lipid mediators regulate T helper cell polarization into Th1/Th2 and Th17 cells, a key event in many immune-mediated diseases. Despite the molecular mechanisms for this effect and the regulatory role of these lipids on other T cell functions have yet to be explored, an extensive number of studies in mice and humans underscore their therapeutic potential.

This concept is supported by the large number of studies using their precursor fatty acids. Of particular importance is the focus on n-3 PUFA that have been explored as anti-inflammatory and immune-protective agents for a range of diseases and relevant experimental models including psoriasis, rheumatoid arthritis, and atherosclerosis (32, 33, 200). A recent study has shown that dietary n-3 PUFA favorably modulate intestinal inflammation in part by downregulating pathogenic T cell responses (201). The Fat-1 mouse, a genetic model that synthesizes long-chain n-3 PUFA de novo, was shown to be relatively resistant to colitis induction due to a reduced differentiation of Th17 cells and related cytokines (202). The immunoregulatory potential of a number of fatty acids has been reported over the years including that of DGLA and GLA (203), stearidonic acid (204) as well as various CLA mixtures used for inflammatory bowel syndrome and human Crohn’s disease (205). Parenteral administration of fatty acids has been shown to ameliorate disease via immunomodulatory effect in a model of rat sepsis (206). A randomized study in patients awaiting carotid endarterectomy showed that n-3 PUFA ethyl esters are incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and T cell infiltration, and increased stability following dietary supplementation with EPA (207).

Furthermore, altering the profile of lipid mediators to strengthen the responses of T cells may be of value to cancer immunotherapy and could result in the development of potent and/or less toxic therapeutics. For example, it is well-documented that most tumors express PGE2 and this can contribute to immune suppression (103, 208). Pharmacological inhibition of PGE2 via non-steroidal anti-inflammatory drugs or EP receptor agonists could be supported or even replaced by systemic administration of EPA, precursor of the less potent eicosanoid PGE3 and the anti-inflammatory resolving series E (RvE) that can tone down the...
### Table 1 | Summary of the main immunoregulatory roles of bioactive lipid mediators related to T cell function and biology.

<table>
<thead>
<tr>
<th>Lipid mediator</th>
<th>Receptor</th>
<th>Effect on T cells</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>PGE₂</td>
<td>EP1, EP2/EP4</td>
<td>Differentiation</td>
<td>(73, 78, 79, 81, 88)</td>
</tr>
<tr>
<td></td>
<td>EP2/EP4</td>
<td>Proliferation</td>
<td>(72, 81, 83, 85)</td>
</tr>
<tr>
<td></td>
<td>EP2/EP4</td>
<td>Cytokine production</td>
<td>(72, 77–80)</td>
</tr>
<tr>
<td></td>
<td>EP2/EP4</td>
<td>Apoptosis</td>
<td>(77, 91)</td>
</tr>
<tr>
<td></td>
<td>EP2/EP4</td>
<td>Motility of T cells</td>
<td>(93–95)</td>
</tr>
<tr>
<td></td>
<td>EP2/EP4</td>
<td>Treg recruitment</td>
<td>(102)</td>
</tr>
<tr>
<td></td>
<td>EP2/EP4</td>
<td>Th1, Th2, Th17 balance</td>
<td>(14, 74–76, 78, 79)</td>
</tr>
<tr>
<td>PGD₂</td>
<td>DP1</td>
<td>Differentiation of Th2; T cell apoptosis</td>
<td>(110, 120, 121)</td>
</tr>
<tr>
<td></td>
<td>DP1, DP2</td>
<td>Recruitment, proliferation of Th2</td>
<td>(111)</td>
</tr>
<tr>
<td></td>
<td>DP2</td>
<td>Activation, cytokine production, trafficking, and motility of Th2</td>
<td>(106, 107, 113–119)</td>
</tr>
<tr>
<td>15d-PGJ₂</td>
<td>DP2</td>
<td>Suppression of Th1 and promotion of Th2</td>
<td>(103, 112)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DC-T cell interaction</td>
<td>(120, 121)</td>
</tr>
<tr>
<td>PGF₂α</td>
<td>FP</td>
<td>Th17 differentiation</td>
<td>(123)</td>
</tr>
<tr>
<td>PGI₂</td>
<td>IP</td>
<td>Th1/Th2 balance</td>
<td>(13)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Th1, Th17 differentiation</td>
<td>(125, 127, 129)</td>
</tr>
<tr>
<td>TXA₂</td>
<td>TP</td>
<td>Inhibition of T cell proliferation</td>
<td>(134)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mediation of DC-T cell interactions</td>
<td>(130)</td>
</tr>
<tr>
<td>LTB₄</td>
<td>BLT1</td>
<td>Homing</td>
<td>(141, 144)</td>
</tr>
<tr>
<td></td>
<td>CysLT1</td>
<td>Differentiation, proliferation, and cytokine production</td>
<td>(146–149)</td>
</tr>
<tr>
<td>CysLTE₄</td>
<td></td>
<td>Th2 differentiation</td>
<td>(151–153)</td>
</tr>
<tr>
<td>12-HETE</td>
<td></td>
<td>Weak T cell chemotaxis</td>
<td>(158, 159)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Metabolic changes</td>
<td>(137)</td>
</tr>
<tr>
<td>15-HETE</td>
<td></td>
<td>Proliferation</td>
<td>(160–162)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Th1 responses</td>
<td>(164)</td>
</tr>
<tr>
<td>LXA₄</td>
<td>BLT1</td>
<td>Cytokine production</td>
<td>(167)</td>
</tr>
<tr>
<td>AEA</td>
<td>CB2</td>
<td>Suppression of Th1 and Th17 proliferation and cytokine release</td>
<td>(185, 186)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inhibition of proliferation; apoptosis via membrane rafts</td>
<td>(187, 189)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Increased Tregs</td>
<td>(184)</td>
</tr>
<tr>
<td>2AG</td>
<td>CB2</td>
<td>T cell migration</td>
<td>(179)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Suppression of cytokine production via PPAR-γ</td>
<td>(189)</td>
</tr>
</tbody>
</table>

PGE₂-mediated effects. Finally, a large number of other investigations have reported that immunonutrition with fatty acids leads to amelioration of a variety of immune-mediated disease by targeting T cell function. Examples include studies showing that the use of n-3 PUFA can improve lung injury and sepsis in animal models, and reduce infectious complications in patients undergoing major surgery and following severe trauma (209–211), while other reports draw attention to the contribution of fatty acids and their mediators in vaccine-induced immunity in infants, the prevention of experimental autoimmune encephalomyelitis through inhibition of Th1/Th17 differentiation by DHA, EPA-mediated protection of cardiac allografts, and amelioration of contact dermatitis following DHA and AA supplements (212–215).

Overall, there is a strong case for further developing therapeutic approaches based on the use of bioactive lipids as immunomodulators. The unmet challenge to fully exploit their therapeutic potential will be to unravel the circuits and molecular mechanisms by which these powerful mediators impact on T cell-mediated immunity.

**ACKNOWLEDGMENTS**

Research support provided by the Wellcome Trust (Anna Nicolaou: WT094028) and British Heart Foundation (Claudio Mauro: FS/12/38/29640 and Federica Marelli-Berg: RG/09/002/2642) is gratefully acknowledged. We thank Dr. Sharon A. Murphy for her contribution to the figures shown in the manuscript.
REFERENCES


Nicolaou et al. Polyunsaturated fatty acid mediators and T cells


Nicolaou et al. Polyunsaturated fatty acid mediators and T cells


Arachidonic acid inhibits 5-lipoxygenase


www.frontiersin.org

February 2014 | Volume 5 | Article 75 | 13

Polyunsaturated fatty acid mediators and T cells


Polyunsaturated fatty acid mediators and T cells

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 19 December 2013; paper pending published: 08 January 2014; accepted: 11 February 2014; published online: 25 February 2014.


This article was submitted to T Cell Biology, a section of the journal Frontiers in Immunology.

Copyright © 2014 Nicolaou, Mauro, Urquhart and Marelly-Berg. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.